1. Scrip
  2. >>Business
  3. >>Earnings

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Ferring HQ
The Swiss group's HQ in Saint-Prex • Source: Ferring

The list of companies that have made money out of a gene therapy is extremely short but Ferring Pharmaceuticals has a case for inclusion given the sales growth last year of its bladder cancer treatment, Adstiladrin.

Key Takeaways
  • The privately held Swiss group posted record sales of €2.34bn, with about half coming from its reproductive medicines franchise
  • Its gene therapy...

The Swiss group has published its financials for 2024 which show that revenues reached €2.34bn ($2.59bn) in 2024, an increase of 7%. The main driver was the privately owned firm’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

More from Women's Health

HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain

 
• By Dexter Jie Yan

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer

 
• By Kevin Grogan

The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.

Veozah Warning On Liver Injury Could Present New Commercial Roadblock

 
• By Jessica Merrill

The US FDA updated labeling for Astellas’ drug for hot flashes after a postmarketing report of a single patient with signs and symptoms of liver injury taking the medicine.